Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YJH-012
- Development stage
- Unknown
- Lead developer
- Livzon Pharmaceutical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
YJH-012 is a GalNAc-conjugated small interfering RNA (siRNA) therapeutic designed to target hepatic xanthine dehydrogenase (XDH, also known as xanthine oxidoreductase or XOR) for the treatment of gout and hyperuricemia. Developed jointly by Livzon Pharmaceutical Group and Youjia (Hangzhou) Bio-medical Technology, YJH-012 utilizes RNA interference (RNAi) to silence XDH expression at the genetic level, thereby inhibiting the synthesis of uric acid in the liver. This liver-targeted approach is designed to provide a long-acting therapeutic effect (potentially 3 to 6 months per single subcutaneous injection) with a favorable safety profile compared to traditional small-molecule xanthine oxidase inhibitors. A Phase I clinical trial (CTR20252501) was initiated in China in 2025 but was subsequently terminated in 2026.
- Other names
- YJH-012 injectionYJH012 injectionYJH 012 injection
02
Targets
XO (Xanthine Oxidoreductase)
Beyond the preview
Go deeper on YJH-012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YJH-012.